Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
|Articles|August 17, 2006
Making better business decisions in the pharma sector
Revolutionizing Pharmaceutical Marketing Effectiveness with Change Management and Technology
Advertisement
Any analysis of future market trends starts from a thorough and accurate understanding of current market conditions, based on the most complete and reliable source of industry data - the reporting companies themselves, in their SEC filings and Annual Reports.
Forecasting the commercial performance of a drug or a pharma company is as much an art as a science, but one widely used measure of future value is the investment analyst consensus forecast, compiled from the reports published by leading financial analysts and brokers.
EvaluatePharma brings together historic sales and detailed company financials with investment analyst consensus sales forecasts in a user-friendly, online service, to deliver unique insight into the past and future performance of the pharmaceuticals and biotechnology sector.
Helping you to make better business decisions
To find out how EvaluatePharma can help you to make better business decisions, visit
Advertisement
Related to this article
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Inovalon's Jen Lamppa on why inaccurate self-reported data is clinical trial enrollment's costliest problem — and how RWD fixes it.
Five major pharma stories in one day — Novo's rebrand and AI bets, Bayer's 30-year CKD first, GSK's T-cell engager, and Sanofi's portfolio exit.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
2
Understanding the Latest with MFN Pricing and What It Means to Pharma
3
The Battle to Own the GLP-1 Patient Journey
4
Novo Announces Drug Discovery Collaboration with Anthropic
5